Medico Intercontinental Ltd - 539938 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dineshkumar Sevantilal Shah & PACs Medico Intercontinental Ltd - 539938 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kunal Narendrabhai Shah & PACs Medico Intercontinental Ltd - 539938 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dilipkumar Bhogilal Shah & PACs Medico Intercontinental Ltd - 539938 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Punit Narendrabhai Shah & PACs Medico Intercontinental Ltd - 539938 - Board Meeting Outcome for Compliances Of Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirements) Regulation, 2015 - Allotment Of Equity Shares Of Face Value Of Rs. 10 On Preferential Issue Basis To Promoters / Non Promoters
In furtherance to the intimation dated 3rd October, 2022 and pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we would like to inform that the Board of Directors of the Company, at its meeting held today approved allotment of the equity shares of the Company by way of private placement on a preferential issue basis to promoters / non promoters, as per the attached file. Medico Intercontinental Ltd - 539938 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
REVISED CONFIRMATION CERTIFICATE - We are enclosing herewith the Revised Confirmation Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 30th September, 2022. Medico Intercontinental Ltd - 539938 - Statement Of Investor Complaints For The Quarter Ended September 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- PUNEETA SHARMADesignation :- Company Secretary and Compliance Officer Medico Intercontinental Ltd - 539938 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith the Confirmation Certificate under Reg. 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 30th September, 2022. Medico Intercontinental Ltd - 539938 - Board Meeting Intimation for Board Meeting In Compliance Of Regulation 29 And 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, As Amended.
Medico Intercontinental Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/10/2022 ,inter alia, to consider and approve With reference to the captioned subject, we wish to inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Monday, 10th October, 2022 at the registered office of the Company situated at 1-5th Floor, Aditraj Arcade, Nr Karma Shreshtha Tower, 100 Ft Rd, Satellite, Ahmedabad, Gujarat - 380015, to inter alia, consider and approve the allotment of Equity Shares of the Company by way of preferential issue to promoters / non promoters, subject to such approvals as may be required under applicable laws and also decide the matters consequential thereto. Medico Intercontinental Ltd - 539938 - Closure of Trading Window
Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 and in compliance with circular no. LIST/COMP/01/2019-20 dated 2nd April, 2019 issued by BSE Limited, we wish to inform you that the 'Trading Window' for dealing in the securities of the Company has been closed and shall remain closed for all the designated persons and their immediate relatives till the conclusion of 48 hours after the declaration of financial results of the company for the quarter and half year ended September 30, 2022. Accordingly, all designated persons and their immediate relatives of the Company have been advised not to trade in the securities of the Company during the aforesaid period of closure of trading window.